Gefitinib and Erlotinib have been used in lung cancer treatments,13,14 and clinical trials in HNSCC have demonstrated that supplementation of cisplatin-based chemotherapy with Gefitinib or Erlotinib will improve the quality of life, but not patient survival rates.15,16 Many studies have indicated that induction of some compensatory survival signalling pathways can limit EGFR inhibitor therapy success.17–20. This evidence concerns the gene EGFR and lung cancer.